Opko Health, Inc 8-K, filed Feb 22, 2021
Opko Health, Inc. (OPK)
8-K
2021-02-22
For: 2021-02-19
View Original
Added on
April 06, 2026
About this 8-K
Opko Health, Inc filed this 8-K on February 22, 2021, reporting on events of February 19, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2021
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (305 ) 575-4100
| Not Applicable | ||
| Former name or former address, if changed since last report | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | |||||||
On February 19, 2021, the Compensation Committee of the Board of Directors (the “Committee”) of OPKO Health, Inc. (the “Company”) held a meeting to review certain compensation matters for the Company’s executive officers and non-executive employees. At the meeting, the Committee: (i) granted stock options to the Company’s named executive officers to purchase the number of shares of the Company’s common stock set forth opposite their names below; (ii) approved a cash bonus payment of $500,000 to Mr. Adam Logal, the Company’s Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer; and (iii) approved an annual salary increase for Mr. Logal from $600,000 to $700,000. The stock options vest ratably over four years, expire on the tenth anniversary of the grant date, and have an exercise price of $4.81 per share, which was the fair market value per share on the date of grant.
Name | Title | Stock Options | |||||||||||||||
Phillip Frost | Chief Executive Officer/Chairman | 400,000 | |||||||||||||||
Jane H. Hsiao | Vice Chairman/Chief Technical Officer | 400,000 | |||||||||||||||
Steven D. Rubin | Executive Vice President | 350,000 | |||||||||||||||
Adam Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer | 350,000 | |||||||||||||||
ITEM 9.01. | Financial Statements and Exhibits. | |||||||
| (d) | Exhibits | |||||||
| Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc. | |||||||||||
By: | /s/ Steven D. Rubin | ||||||||||
Date: February 22, 2021 | Name: | Steven D. Rubin | |||||||||
Title: | Executive Vice President-Administration | ||||||||||